AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15253688 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept (12 weekly injections followed by 12 treatment-free weeks)
Number of subjects: 1300
Study 15253688 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept (subsequent courses)
Number of subjects: 1300
Study 15253688 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept (multiple courses)
Number of subjects: 1300
Study 15253688 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept
Number of subjects: 1300
Study 11687526 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical timolol
Number of subjects: 90
Study 11687526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 9456560 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Networks (ANN) for analysis of visual evoked potentials (VEP)
Number of subjects: 96
Study 9456560 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual evoked potentials (VEP) analysis
Number of subjects: 96
Study 9456560 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Networks (ANN)
Number of subjects: 96
Study 7928930 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary education protocol delivered by GPs, community nurses, asthma nurses, and doctors consisting of 16 educational modules.
Number of subjects: 0
Study 7928930 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary education protocol
Number of subjects: 0
Study 7928930 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 3789237 — intervention group
Group type: EXPERIMENTAL
Intervention: Denver Developmental Screening Test (DDST) with community health intervention program for positive screenees
Number of subjects: 4797
Study 3789237 — intervention group
Group type: EXPERIMENTAL
Intervention: Denver Developmental Screening Test (DDST) with no intervention for positive screenees
Number of subjects: 4797
Study 3789237 — intervention group
Group type: COMPARATOR
Intervention: No screening test
Number of subjects: 4797
Study 3789237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program children
Number of subjects: 4797
Study 3789237 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with positive preschool DDSTs
Number of subjects: 4797
Study 30249211 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy
Number of subjects: 0
Study 30249211 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination nivolumab/ipilimumab
Number of subjects: 0
Study 30249211 — intervention group
Group type: COMPARATOR
Intervention: Standard of care neoadjuvant radiation therapy
Number of subjects: 0
Study 26147943 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence supported smoking cessation therapy (including pharmacotherapy and behavioral support)
Number of subjects: 0
Study 26147943 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking behaviors and motivations for quitting
Number of subjects: 0
Study 26147943 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous attempts to stop smoking
Number of subjects: 0
Study 26147943 — intervention group
Group type: EXPERIMENTAL
Intervention: Future recommendations
Number of subjects: 0
Study 25748868 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxy consent from next of kin (NOK)
Number of subjects: 171
Study 25748868 — intervention group
Group type: EXPERIMENTAL
Intervention: Consent from general practitioner (GP)
Number of subjects: 171
Study 23102691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Number of subjects: 42
Study 23102691 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 21218747 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole (initial dose of 80 mg, followed by 8 mg/h infusion)
Number of subjects: 108
Study 21218747 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ranitidine (100 mg bolus, followed by 100 mg boluses every 6 hours for 72 hours)
Number of subjects: 108
Study 21218747 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole
Number of subjects: 108
Study 21218747 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ranitidine
Number of subjects: 108
Study 18523394 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic esophageal imaging by oral administration of contrast media
Number of subjects: 468
Study 18523394 — intervention group
Group type: COMPARATOR
Intervention: Ross technique (control group)
Number of subjects: 468
Study 18523394 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 468
Study 15926017 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 10 mg daily for two months
Number of subjects: 18
Study 15926017 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-oral device appliance for two months
Number of subjects: 18
Study 15926017 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 18
Study 12683743 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV Harm Reduction Program (HHRP+)
Number of subjects: 90
Study 12683743 — intervention group
Group type: COMPARATOR
Intervention: Active control with harm reduction components recommended by the National AIDS Demonstration Research Project
Number of subjects: 90
Study 10340911 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (250 mg once daily for 14 days)
Number of subjects: 9
Study 10340911 — intervention group
Group type: COMPARATOR
Intervention: Control group (poor metabolizers)
Number of subjects: 9
Study 7569455 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms of estrogen and 300 micrograms of progestogen (Group 2)
Number of subjects: 371
Study 7569455 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 micrograms of estrogen and 500 micrograms of progestogen (Group 3)
Number of subjects: 371
Study 7569455 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms of levonorgestrel followed by intrauterine device or contraceptives of group 2 or group 3 (Group 4)
Number of subjects: 371
Study 7569455 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine devices (Group 1)
Number of subjects: 371
Study 1775605 — intervention group
Group type: EXPERIMENTAL
Intervention: Arecoline at 4 mg/day
Number of subjects: 8
Study 1775605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 399858 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol dry powder (200 micrograms per capsule)
Number of subjects: 38
Study 399858 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol aerosol
Number of subjects: 38
Study 399858 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotahaler (device for powder administration)
Number of subjects: 38
Study 31439599 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Number of subjects: 240
Study 31439599 — intervention group
Group type: COMPARATOR
Intervention: Levocetirizine and prednisone
Number of subjects: 240
Study 27469608 — intervention group
Group type: EXPERIMENTAL
Intervention: Right internal jugular vein (IJV) CVC placement
Number of subjects: 60
Study 27469608 — intervention group
Group type: EXPERIMENTAL
Intervention: Left internal jugular vein (IJV) CVC placement
Number of subjects: 60
Study 27469608 — intervention group
Group type: COMPARATOR
Intervention: Postoperative assessment using chest radiography (CXR)
Number of subjects: 60
Study 25996371 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet plus culturally tailored text message group
Number of subjects: 252
Study 25996371 — intervention group
Group type: COMPARATOR
Intervention: Control group (Internet physical activity program)
Number of subjects: 252
Study 22791300 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at PC-6 acupuncture points before HUT/LBNP
Number of subjects: 30
Study 22791300 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at PC-6 acupuncture points during HUT/LBNP
Number of subjects: 30
Study 22791300 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture (EA) at a non-acupoint
Number of subjects: 30
Study 22791300 — intervention group
Group type: COMPARATOR
Intervention: No electroacupuncture (control group)
Number of subjects: 30
Study 21044863 — intervention group
Group type: EXPERIMENTAL
Intervention: pLCHS‐hph vector
Number of subjects: 0
Study 21044863 — intervention group
Group type: EXPERIMENTAL
Intervention: pChG‐bar vector
Number of subjects: 0
Study 19917927 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by concurrent chemoradiotherapy (CRT)
Number of subjects: 49
Study 16460916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 0
Study 16460916 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive counselling
Number of subjects: 0
Study 16460916 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 14991626 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetic mesh placed in a sublay position
Number of subjects: 54
Study 14991626 — intervention group
Group type: COMPARATOR
Intervention: Conventional stoma
Number of subjects: 54
Study 11277642 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin alone (300 mg/m2 every 28 days for five cycles)
Number of subjects: 190
Study 11277642 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin plus epidoxorubicin (120 mg/m2 and 300 mg/m2 every 28 days for five cycles)
Number of subjects: 190
Study 11229179 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 32
Study 11229179 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 32
Study 11229179 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 32
Study 8371471 — intervention group
Group type: EXPERIMENTAL
Intervention: Class I antiarrhythmic agents
Number of subjects: 98000
Study 8371471 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (class II agents)
Number of subjects: 98000
Study 8371471 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (class III agent)
Number of subjects: 98000
Study 8371471 — intervention group
Group type: EXPERIMENTAL
Intervention: Class IV agents (calcium channel blockers)
Number of subjects: 98000
Study 3088642 — intervention group
Group type: COMPARATOR
Intervention: 0% THC marijuana cigarettes
Number of subjects: 7
Study 3088642 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.01% THC marijuana cigarettes
Number of subjects: 7
Study 3088642 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.84% THC marijuana cigarettes
Number of subjects: 7
Study 3088642 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.84% THC marijuana cigarettes
Number of subjects: 7
Study 29334277 — intervention group
Group type: EXPERIMENTAL
Intervention: DPOAE screening conducted by village health workers (VHWs)
Number of subjects: 119
Study 29334277 — intervention group
Group type: COMPARATOR
Intervention: Tele‐ABR (gold standard)
Number of subjects: 119
Study 27604619 — intervention group
Group type: EXPERIMENTAL
Intervention: Early comprehensive patient care (ECPC)
Number of subjects: 183
Study 27604619 — intervention group
Group type: COMPARATOR
Intervention: Standard patient care (SPC)
Number of subjects: 183
Study 24799649 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand sanitizer dispenser present on the anesthesia machine
Number of subjects: 40
Study 24799649 — intervention group
Group type: COMPARATOR
Intervention: No hand sanitizer dispenser present
Number of subjects: 40
Study 23082391 — intervention group
Group type: EXPERIMENTAL
Intervention: Restored with resin composite using total acid etch adhesive technique (37% H3PO4 + Single Bond + Z250)
Number of subjects: 10
Study 23082391 — intervention group
Group type: EXPERIMENTAL
Intervention: Restored with resin composite but without acid etching (Single Bond + Z250)
Number of subjects: 10
Study 23082391 — intervention group
Group type: COMPARATOR
Intervention: Sound blocks (control group)
Number of subjects: 10
Study 20106932 — intervention group
Group type: EXPERIMENTAL
Intervention: High red meat diet
Number of subjects: 14
Study 20106932 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined red meat/fish diet
Number of subjects: 14
Study 20106932 — intervention group
Group type: EXPERIMENTAL
Intervention: High fish diet
Number of subjects: 14
Study 16670695 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycemic load breakfast meal (farina)
Number of subjects: 45
Study 16670695 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic load breakfast meal (fiber-loop cereal with psyllium)
Number of subjects: 45
Study 16670695 — intervention group
Group type: COMPARATOR
Intervention: Standardized lunch after both breakfast types
Number of subjects: 45
Study 14967281 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight microtip
Number of subjects: 48
Study 14967281 — intervention group
Group type: COMPARATOR
Intervention: Kelman microtip
Number of subjects: 48
Study 11371732 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic-enteric (SE) drainage
Number of subjects: 54
Study 11371732 — intervention group
Group type: COMPARATOR
Intervention: Portal-enteric (PE) drainage
Number of subjects: 54
Study 9209898 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal estriol (0.5 mg daily)
Number of subjects: 29
Study 9209898 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta‐estradiol (0.05 mg daily)
Number of subjects: 29
Study 9209898 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 29
Study 8272550 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy (CDP, 2 cycles) followed by radical surgery
Number of subjects: 54
Study 8272550 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (ERT 45 Gy + IRT or END-RT 20-25 Gy)
Number of subjects: 54
Study 3040605 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5-10 mg twice daily)
Number of subjects: 55
Study 3040605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 29302858 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesilate 1.4 mg/m2 intravenously on days 1 and 8
Number of subjects: 392
Study 29302858 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine 1.25 g/m2 orally twice daily on days 1-14 (21-day cycles)
Number of subjects: 392
Study 29302858 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesilate
Number of subjects: 392
Study 29302858 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 392
Study 26283647 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 93
Study 26283647 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 93
Study 26283647 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized seated heel‐rises
Number of subjects: 93
Study 26283647 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-leg standing heel‐rises
Number of subjects: 93
Study 24584818 — intervention group
Group type: EXPERIMENTAL
Intervention: Spouse-assisted lifestyle intervention (9 monthly telephone calls to patients and spouses)
Number of subjects: 251
Study 24584818 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 251
Study 22433632 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of wireless phones
Number of subjects: 331
Study 22433632 — intervention group
Group type: EXPERIMENTAL
Intervention: Different phone types (calculated separately)
Number of subjects: 331
Study 22433632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative use divided into three groups (1‐1000, 1001‐2000 and >2000 h)
Number of subjects: 331
Study 22433632 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of wireless phones (light-to-moderate)
Number of subjects: 331
Study 20507841 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 3% gel treatment
Number of subjects: 32
Study 20507841 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 32
Study 18826094 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographically guided percutaneous ethanol injection (4 injections on average in the first group, 6 injections in the second group, 2-10 ml ethanol per injection)
Number of subjects: 32
Study 18826094 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographically guided percutaneous ethanol injection (6 injections)
Number of subjects: 32
Study 18826094 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 32
Study 15975536 — intervention group
Group type: COMPARATOR
Intervention: 7-day triple therapy with esomeprazole 20mg b.i.d., clarithromycin 500 mg b.i.d. and amoxycillin 1g b.i.d.
Number of subjects: 133
Study 15975536 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy comprising of the same regimen plus lactoferrin 200mg b.i.d.
Number of subjects: 133
Study 15975536 — intervention group
Group type: COMPARATOR
Intervention: Side effects following triple regimen
Number of subjects: 133
Study 15975536 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects following quadruple regimen
Number of subjects: 133
Study 15333416 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (50 microg. kg(‐1). min(‐1)) infused IV over 60 min
Number of subjects: 20
Study 15333416 — intervention group
Group type: COMPARATOR
Intervention: Placebo infused IV over 60 min
Number of subjects: 20
Study 11301934 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in rapeseed oil
Number of subjects: 20
Study 11301934 — intervention group
Group type: COMPARATOR
Intervention: Diet rich in saturated fat
Number of subjects: 20
Study 9249934 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (tacrolimus 0.10 mg/kg and prednisolone)
Number of subjects: 130
Study 9249934 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (tacrolimus 0.06 mg/kg, prednisolone, and azathioprine)
Number of subjects: 130
Study 9249934 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy
Number of subjects: 130
Study 9249934 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 130
Study 8388030 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-interferon preparations (exact dosage and duration not specified)
Number of subjects: 42
Study 8388030 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 nuns with no lifetime sexual exposure)
Number of subjects: 42
Study 3434169 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium
Number of subjects: 60
Study 3434169 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 60
Study 29462266 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice daily for 5 days
Number of subjects: 0
Study 29462266 — intervention group
Group type: COMPARATOR
Intervention: Rifampin 600 mg once daily for 5 days
Number of subjects: 0
Study 28579233 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine with 120μg RSV F protein and 0.4mg aluminum
Number of subjects: 0
Study 28579233 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of 60μg RSV F protein and 0.8mg aluminum
Number of subjects: 0
Study 28579233 — intervention group
Group type: COMPARATOR
Intervention: All formulations (including placebo)
Number of subjects: 0
Study 28579233 — intervention group
Group type: EXPERIMENTAL
Intervention: Active vaccinees
Number of subjects: 0
Study 25647729 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir 1% gel
Number of subjects: 15
Study 25647729 — intervention group
Group type: COMPARATOR
Intervention: Nonoxynol-9 2% gel
Number of subjects: 15
Study 25647729 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 15
Study 25647729 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 15
Study 24127924 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen-rich water (HRW) 1200-1800 mL/day, twice daily for 6 weeks
Number of subjects: 60
Study 24127924 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment alone
Number of subjects: 60
Study 24127924 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 60
Study 21168920 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 225
Study 21168920 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 225
Study 18081359 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio‐HA
Number of subjects: 321
Study 18081359 — intervention group
Group type: COMPARATOR
Intervention: hylan G‐F 20
Number of subjects: 321
Study 16812974 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 8888
Study 16812974 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20-40 mg
Number of subjects: 8888
Study 12962763 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 240
Study 12962763 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 240
Study 10661482 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO therapy
Number of subjects: 27
Study 10661482 — intervention group
Group type: COMPARATOR
Intervention: No rhEPO therapy
Number of subjects: 27
Study 10661482 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (10 mg, 3 times a week)
Number of subjects: 27
Study 10661482 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid deficiency
Number of subjects: 27
Study 10661482 — intervention group
Group type: COMPARATOR
Intervention: Comparison of controls and dialyzed patients on rhEPO therapy
Number of subjects: 27
Study 10661482 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between serum erythropoietin and folic acid levels
Number of subjects: 27
Study 10661482 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between folic acid and homocysteine levels
Number of subjects: 27
Study 8713770 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 948
Study 8713770 — intervention group
Group type: COMPARATOR
Intervention: Non-aprotinin (Control)
Number of subjects: 948
Study 1432502 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect ophthalmoscope and protractor method
Number of subjects: 20
Study 1432502 — intervention group
Group type: COMPARATOR
Intervention: Fundus photography
Number of subjects: 20
Study 1432502 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 20
Study 3881242 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily
Number of subjects: 334